Has Gregory Beatty received payments from drug or device companies?

Yes. Drug and device makers reported $43,513 in general payments to Gregory Beatty across 41 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gregory Beatty did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gregory Beatty come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gregory Beatty

Medical Oncology · Philadelphia, PANPI 1730242363

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $36,078 of the $43,513 with a category attached, or 82.9%. 11 manufacturers reported payments, led by Incyte Corporation at 45.6% of the total. Reporting peaked in 2021 at $13,284 and has fallen 94.6% since, to $713 in 2025.

$43,513in general payments, 2019–2025

Across 41 payments — averaging $1061.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$20K
EMD Serono Research & Development Institute, Inc.$6K
Boehringer Ingelheim$5K
E.r. Squibb & Sons, L.L.C.$4K
Biomarin Pharmaceutical Inc.$3K
Legend Biotech USA Inc.$2K
plus $3K from 5 others

$4,280,622in research payments, 2019–2025

Across 96 payments — averaging $44,590 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Incyte Corporation$3.8M
E.r. Squibb & Sons, L.L.C.$476K
Genmab BV$26K
Takeda Pharmaceuticals U.S.A., Inc.$4K

What the payments were for

Consulting fees$36,07883%
Speaking & faculty fees$6,73915%
Travel & lodging$3611%
Food & beverage$3361%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	12	$19,859
EMD Serono Research & Development Institute, Inc.	2	$5,938
Boehringer Ingelheim	18	$5,386
E.r. Squibb & Sons, L.L.C.	1	$4,152
Biomarin Pharmaceutical Inc.	1	$2,600
Legend Biotech USA Inc.	1	$2,338
Ventana Medical Systems, Inc.	1	$1,500
Seagen Inc.	2	$665
Janssen Research & Development, LLC	1	$515
Merck	1	$500
F. Hoffmann-la Roche AG	1	$61

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BENCHMARK IHC/ISH PLATFORMS & REAGENTS$1,500
KEYTRUDA$500

How this compares

$43,513 in reported general payments places this provider in the 85th percentile of 238 medical oncology providers in Pennsylvania.

See all medical oncology providers in Pennsylvania →

Other medical oncology in Philadelphia

Carl JunePhiladelphia$9M
Shayma KazmiPhiladelphia$619K
Marcia BrosePhiladelphia$260K
Adam CohenPhiladelphia$239K
Daniel HallerPhiladelphia$227K
Edith MitchellPhiladelphia$220K
Elizabeth PlimackPhiladelphia$190K
Alexander PerlPhiladelphia$176K
Martin EdelmanPhiladelphia$157K
Jean-Pierre IssaPhiladelphia$147K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →